A Human Model for Studying and Treating Rett Syndrome and Other Autism Spectrum Disorders

Tech ID: 22694 / UC Case 2011-281-0

BACKGROUND
Mutations and duplication of the X-linked MeCP2 gene are observed in several disorders, such as Rett Syndrome (RTT), Autism, severe neonatal encephalopathy, schizophrenia and X-linked mental retardation. As MeCP2 plays an important role in the pathogenesis of multiple mental disorders, the investigation of MeCP2 function and regulatory pathways may show promise for developing broad-spectrum therapies. Downstream MeCP2 target genes, such as the calcium channel TRPC6, can have a secondary impact on the cell and predispose the individual to autism.

TECHNOLOGY DESCRIPTION
UCSD researchers have demonstrated that RTT-derived neurons, deriving from patients carrying different MeCP2 mutations, can recapitulate some of the disease aspects, such as decreased in spine density, reduced glutamatergic synapses and defective neuronal networks. They also found drugs able to rescue synaptic deficiency in RTT neurons, as a proof-of-principle for a future drug screening platform. Together, such results suggest that RTT, and likely other neurological disorders can be modeled using induced pluripotent stem cells (iPSC) technology to investigate the molecular mechanisms underlying their abnormalities. The same technology can be combined with genomics to study idiopathic (sporadic) types of autism.

APPLICATIONS
This cellular model has the potential to lead to the discovery of new compounds to treat RTT, autism and other neurodevelopmental diseases. As another example, this platform was used to detect alteration in TRPC6 expression in an autistic patient. Using iPSC-derived neurons, it was possible to design a personalized medicine using nutritional complements in patient’s diet.

ADVANTAGES
Automated and high through screening system with highly efficient neuronal and astrocyte differentiation protocol for a cellular and molecular read outs, such as synapse formation.

Stage of development: Screening system with several iPSC cell lines carrying different MeCP2 and TRPC6 mutations have been used to identify promising regulatory pathways and potential drug candidates.

STATE OF DEVELOPMENT
Screening system with several iPSC cell lines carrying different MeCP2 and TRPC6 mutations have been used to identify promising regulatory pathways and potential drug candidates.

INTELLECTUAL PROPERTY INFO
Patent pending. PCT application WO 2013163455 A2 titled “A drug screening platform for Rett syndrome”

RELATED MATERIALS

PATENT STATUS

<table>
<thead>
<tr>
<th>Country</th>
<th>Type</th>
<th>Number</th>
<th>Dated</th>
<th>Case</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States Of America</td>
<td>Published Application</td>
<td>20150119327</td>
<td>04/30/2015</td>
<td>2011-281</td>
</tr>
</tbody>
</table>

OTHER INFORMATION
KEYWORDS
Rett Syndrome, Autism Spectrum Disorders, Neurodevelopmental, Drug screening, MeCP2, TRPC6

CATEGORIZED AS
Medical
Disease: Central Nervous System
Screening
Research Tools
Screening Assays

RELATED CASES
2011-281-0